What is the role of combination therapy (insulin plus oral medication) in type 2 diabetes? by Eskesen, Staci et al.
From the 
Family Physicians
Inquiries Network
CLINICAL INQUIRIES
❚ Evidence summary
A systematic review evaluated beginning
combination therapy (adding insulin to
oral medication) compared with switch-
ing to insulin alone in patients with type
2 diabetes mellitus with inadequate
glycemic control on oral medication.1
Twenty RCTs studied a total of 1811
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What is the role of combination
therapy (insulin plus oral 
medication) in type 2 diabetes?
E V I D E N C E - B A S E D A N SW E R
C L I N I C A L C O M M E N TA R Y
Educate patients from the time 
of diagnosis that insulin is not a failure
Combination therapy for patients with type 2
diabetes is a safe and effective stepping
stone between oral therapy and insulin ther-
apy. Unfortunately, significant barriers remain
to getting insulin started when oral agents
alone are insufficient. Patients often do not
understand the common need for insulin
therapy as type 2 diabetes advances, and
some physicians continue to use the threat
of insulin as a punitive incentive to promote
patient compliance. It is little wonder that
many patients perceive a physician’s eventu-
al recommendation for insulin therapy as a
personal failure. Patients are also concerned
about the discomfort, inconvenience, and
risk of insulin injections. Physicians should
focus on educating their patients from the
time of diagnosis that insulin is not a failure,
but just another tool that will help them
achieve their blood sugar goals.
Vincent Lo, MD
San Joaquin General Hospital, French Camp, Calif
Combination therapy using insulin plus met-
formin (Glucophage), a sulfonylurea, or both
produces glycemic control comparable with
using insulin alone, but there is less weight
gain when metformin is used (strength of
recommendation [SOR]: B, based on 
systematic review of randomized controlled
trials [RCTs] with some heterogeneity).
Combination therapy using insulin and
pioglitazone (Actos) reduces glycosylated
hemoglobin (HbA1c) more than either insulin
alone or adding pioglitazone to a sulfony-
lurea, but results in more weight gain (SOR:
A, based on RCT). Using insulin glargine
(Lantus) in combination therapy produces
fewer nocturnal hypoglycemic events than
using neutral protamine Hagedorn (NPH)
insulin, while producing equivalent HbA1c
reduction (SOR: B, based on RCT).
When the HbA1c is high (above 9.0% to
9.5%) on 1 or 2 oral agents, beginning 
combination therapy is more effective than
adding another oral agent (SOR: B, based
on subpopulation analysis in RCTs).
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patients; glycemic control was the pri-
mary outcome measure. Oral medication
comprised either sulfonylureas (75%),
metformin (4%), or both (21%).
Individual studies used different insulin
dosing schedules and statistical measures.
However, overall, combination therapy
provided glucose control comparable
with insulin alone. In only 1 small, low-
quality study did insulin plus metformin
reduce HbA1c more than other combina-
tion therapy regimens or insulin alone.
Ten studies reported a trend toward less
weight gain with combination therapy
that included metformin. Fourteen studies
found the same incidence of hypo-
glycemic episodes in combination therapy
and insulin alone. 
Three later RCTs of overweight
patients with inadequate control on oral
agents (HbA1c >7% on a sulfonylurea,
metformin, or both) also compared
beginning combination therapy with
switching to insulin alone (with 70/30 or
NPH insulin twice daily). In one study
with 64 patients followed for 12 months,
HbA1c fell by 0.14% less (nonsignificant)
in the combination therapy group (bed-
time NPH plus sulfonylurea and met-
formin) than in the insulin alone group
(70/30 twice daily).2 The combination
therapy group gained significantly less
weight than the insulin-alone group (1.3
kg vs 4.2 kg; P=.01). 
In the second study of 261 patients,
the combination therapy group
(glimepiride [Amaryl] plus bedtime NPH)
had a significantly higher HbA1c after 9
months than 2 groups using insulin alone
(twice daily 70/30, and twice daily NPH
insulin) (8.9% vs 8.3% and 8.4%).3
Mean weight gain was similar in all 3
groups but only a minority of patients
reached a target HbA1c of 6.5%. In the
final study of only 16 patients, HbA1c
after 6 months improved significantly and
equally in both groups (baseline: 8.3%,
combination therapy final: 6.8%; insulin
alone final: 7.0%). However, the combi-
nation therapy group gained significantly
less weight.4
An open-label RCT with 341 patients
who were inadequately controlled on
metformin compared beginning combina-
tion therapy (biphasic insulin aspart
30/70 [Novolog Mix 70/30] and met-
formin) with switching to insulin alone
(biphasic insulin aspart 30/70).5 A third
group added a second oral medication
(sulfonylurea and metformin). After 16
weeks, patients taking combination ther-
apy had a significantly lower HbA1c than
those on insulin alone (treatment differ-
ence 0.39%, P=.007). 
Overall, combination therapy and 2
oral medications reduced HbA1c by the
same amount, but combination therapy
reduced HbA1c more in a subpopulation
of patients with HbA1c >9.0% at baseline
(treatment difference 0.46%, P=.027).
The group on insulin alone weighed sig-
nificantly more (4.6 kg, P<.001) at the
end of the trial than the group taking 2
oral medications.
An open-label RCT of 756 patients
with inadequate glycemic control (HbA1c
>7.5%, mean 8.6%) on either 1 or 2 oral
agents (70% taking both metformin and
a sulfonylurea) compared combination
therapy using bedtime insulin glargine
with combination therapy using morning
NPH.6 Each group titrated insulin doses
to achieve a target fasting glucose ≤100.
By 24 weeks, both groups had equivalent-
ly reduced HbA1c (mean HbA1c=6.96%
with glargine, and 6.97% with NPH;
P=NS), but fewer patients experienced
nocturnal hypoglycemia with glargine
than with NPH (33.2% vs 26.7%,
P<.05).
Another open-label RCT evaluated
281 patients with at least 3 months of
inadequate glycemic control (HbA1c=
7.4%–14.7%) on a sulfonylurea.7
Patients were randomized to a) switching
to a combination of biphasic insulin
aspart 30/70 plus pioglitazone, b) adding
pioglitazone to the sulfonylurea, or c)
switching to insulin alone (biphasic
insulin aspart 30/70). After 18 weeks,
insulin plus pioglitazone reduced HbA1c
significantly more than either glyburide
When HbA1c is
high, beginning
combination 
therapy is more
effective than
adding another
oral agent
1002 VOL 55, NO 11 / NOVEMBER 2006  THE JOURNAL OF FAMILY PRACTICE
FAST TRACK
C
LI
N
IC
A
L
IN
Q
U
IR
IE
S
JFP_1106_CIs.Final  10/17/06  1:51 PM  Page 1002
Combination therapy in type 2 diabetes ▲
VOL 55, NO 11 / NOVEMBER 2006 1003www. j f p o n l i n e . c om
plus pioglitazone (P=.005) or insulin
alone (P=.005). However, the insulin plus
pioglitazone group had the most weight
gain (mean 4 kg, similar to other pioglita-
zone trials). There were no major hypo-
glycemic events. 
Another open-label RCT evaluated
217 patients inadequately controlled
(HbA1c=7.5%–11%) on a 2-drug oral
regimen (metformin and a sulfonylurea,
each drug dosed at ≥50% of the recom-
mended maximum), randomized to add
either insulin glargine or rosiglitazone
(Avandia).8 Both groups reduced HbA1c
equivalently after 24 weeks (–1.7% for
glargine vs –1.5% for rosiglitazone).
However, in patients with a baseline
HbA1c >9.5%, adding insulin glargine
reduced HbA1c significantly more than
rosiglitazone.
Recommendations by others
A comparative analysis of guidelines on
diabetes from 13 different countries
(including the US) found general agree-
ment in the recommendation to add a sec-
ond oral agent to maximum doses of an
initial agent in patients with poor
glycemic control.9 However, no consensus
was reached on the value or indications of
combination therapy with oral agents and
insulin. 
The European Diabetes Policy Group
recommends adding a second oral agent
when the maximum dose of a single
agent is reached, and using triple therapy
when targets are not reached on maxi-
mum tolerated doses of 2 agents.
Continued therapy with oral agents is
advised when initiating insulin.10
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